Halozyme Therapeutics, Inc. · NASDAQ:HALO

Torley Helen sold 60,000 Halozyme Therapeutics, Inc. shares (Form 4)

Traded Aug 17 to Aug 19, 2026 · Filed Aug 19, 2026

From Aug 17 to Aug 19, 2026, Torley Helen (Director, PRESIDENT AND CEO) sold 60,000 Halozyme Therapeutics, Inc. shares at an average US$104.59 for US$6.28M under a trading plan, leaving 767,780 shares. Filed Aug 19, 2026 (Form 4).

Sold
60,000 shares
Price
US$104.59 average (US$98.96 to US$107.77)
Value
US$6.28M
Holding after
767,780 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Director, PRESIDENT AND CEO

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Aug 17, 2026Common StockOption exercise20,000US$18.41787,780Direct
Aug 17, 2026Common StockSale900US$98.96786,880Direct
Aug 17, 2026Common StockSale500US$100.46786,380Direct
Aug 17, 2026Common StockSale2,100US$101.77784,280Direct
Aug 17, 2026Common StockSale9,000US$102.55775,280Direct
Aug 17, 2026Common StockSale7,500US$103.48767,780Direct
Aug 18, 2026Common StockOption exercise20,000US$18.41787,780Direct
Aug 18, 2026Common StockSale5,703US$103.08782,077Direct
Aug 18, 2026Common StockSale4,897US$104.11777,180Direct
Aug 18, 2026Common StockSale9,400US$104.87767,780Direct
Aug 19, 2026Common StockOption exercise20,000US$18.41787,780Direct
Aug 19, 2026Common StockSale7,200US$106.36780,580Direct
Aug 19, 2026Common StockSale9,600US$107.22770,980Direct
Aug 19, 2026Common StockSale3,200US$107.77767,780Direct

Source

View original at SEC

Related